News | Radiation Therapy | November 22, 2016

New Standard of Care Offers Lower Toxicity, Shorter Treatment Times and Improved Cosmetic Outcomes for Women with Early Stage Breast Cancer

ASTRO updates clinical guidance on accelerated radiation therapy for breast cancer 

Breast brachytherapy, partial breast irratiation

Accelerated Partial Breast Irradiation (APBI) brachytherapy for breast cancer. Image courtesy of Elekta.

 

The American Society for Radiation Oncology (ASTRO) today announced an update to its Evidence-Based Consensus Statement for the use of Accelerated Partial Breast Irradiation (APBI) brachytherapy to include younger patients and those with low-risk ductal carcinoma in situ (DCIS).

APBI brachytherapy is a targeted form of radiation that is delivered after surgical excision of the tumor (lumpectomy) to only the area of the breast where the cancer was removed. This is accomplished by introducing a radiation source through a series of narrow tubes or struts that are placed inside the tumor cavity. APBI brachytherapy offers less radiation exposure, reduced treatment time, better cosmetic outcomes and more flexibility with respect to future treatment options.

ASTRO updated its APBI Consensus Statement to reflect data from three large-scale randomized trials evaluating APBI vs. WBI. The data from these trials were sufficiently robust that the committee voted unanimously to change the guidelines, expanding the group of patients for whom APBI brachytherapy is suitable, which now includes patients ≥50 years of age (previously, patients ≥60 years of age were included).

“Evidence-based guidelines have the potential to fundamentally alter clinical practice. These important changes to ASTRO’s guidelines were based on a systematic review of 45 published clinical studies, significantly expanding the eligible patient population,” said Atif J. Khan, MD, Director of Brachytherapy Services at the Rutgers Cancer Institute of New Jersey in New Brunswick.  “Several recent clinical studies, including well-designed randomized trials directly comparing APBI to WBI, demonstrate that APBI brachytherapy offers potential advantages over WBI including a shorter course of treatment and decreased radiation while maintaining similarly low rates of cancer recurrence. We anticipate that ASTRO’s recommendations will drive significant changes in how clinicians approach early stage breast cancer treatment.”

Two decades of data have established breast conservation therapy (BCT) as the standard of care in early stage breast cancer. The traditional approach for radiation therapy as part of BCT has been a full course of whole breast irradiation (WBI), which exposes the entire breast and surrounding critical structures to radiation and requires daily treatments for four to six-and-a-half weeks.

“APBI brachytherapy is an attractive treatment option for many women with early stage breast cancer. It offers several advantages over WBI, while maintaining similar clinical outcomes, including the possibility of less radiation exposure to critical organs such as the heart, and improved cosmetic outcomes,” said Julie A. Margenthaler, M.D., FACS, professor, division of general surgery at Washington University School of Medicine, chair of American Society of Breast Surgeons communications committee. “With the wide body of evidence supporting the safety and efficacy of APBI for women with early stage breast cancer and the guidelines update from ASTRO, we should soon see more widespread adoption of this clinically proven and convenient approach that targets only the tissue at risk and is kinder to patients. Indeed, treating these women with WBI may represent overtreatment.”

Elekta and Cianna Medical support ASTRO’s APBI guidelines update and are committed to improving cancer care through developing innovative medical technologies and educating women about their options. The companies encourage women to learn more about their treatment options and talk to their doctors about selecting the best individualized care plan. Additional information about APBI is also available on the ASTRO website and at bc5project.com.

“After being diagnosed with an invasive ductal carcinoma in my left breast, I underwent six weeks of radiation therapy with many unpleasant side effects,” said Rochelle Colon, a breast cancer survivor. “I remained cancer free for 15 years and then it came back on my opposite breast. Fortunately, this time my cancer was treated with APBI brachytherapy in only five short days and I experienced none of the pain or discomfort that I had previously with a longer course of radiation.”

 

For more information: www.astro.org

Related Content

Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark